Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx, Inc. (NASDAQ: RNXT) announced the issuance of US patent number 11,541,211 on January 3, 2023, covering methods for treating cholangiocarcinoma through targeted delivery of therapeutic agents. This patent is their eighth in the US, contributing to a robust intellectual property portfolio that includes 8 US method and device patents, one EU delivery system patent, and several pending patents globally. Additionally, the patent strengthens the seven years of market exclusivity RenovoRx holds for its lead product candidate, RenovoGem™, under FDA's Orphan Drug designation.
RenovoRx, Inc. (Nasdaq: RNXT) announced the acceptance of four clinical data abstracts supporting its lead oncology candidate, RenovoGem, at the 2023 ASCO Gastrointestinal Cancers Symposium, scheduled for January 19-21, 2023, in San Francisco, California.
RenovoGem, evaluated in a Phase III trial for Locally Advanced Pancreatic Cancer (LAPC), employs a proprietary delivery system via RenovoTAMP. Upcoming plans include an interim analysis of the TIGeR-PaC study and investigations into extrahepatic Cholangiocarcinoma (eCCA).
RenovoRx (Nasdaq: RNXT) announced that its therapy platform, RenovoTAMP, was featured in two presentations at the Advanced Interventional Management Symposium. Dr. Ripal Gandhi discussed the potential of RenovoTAMP for treating locally advanced pancreatic cancer (LAPC), emphasizing a Phase III study, TIGeR-PaC, aimed at extending survival and reducing side effects. Dr. Christopher Laing explored RenovoTAMP's applications in pancreatic and bile duct cancers. The company aims to enhance chemotherapy delivery while minimizing toxicity, holding Orphan Drug Designation for its treatment approaches.
RenovoRx, Inc. (NASDAQ: RNXT) reported its financial results for Q3 2022, highlighting a net loss of $2.1 million, up from $1.5 million in Q3 2021. Cash and equivalents stood at $8.1 million as of September 30, 2022. The company plans to conduct a prospective interim analysis of its Phase III TIGeR-PaC trial for pancreatic cancer treatment, potentially revolutionizing care in this area. A new clinical trial for extrahepatic cholangiocarcinoma is also set to launch in late 2022 or early 2023. General and administrative expenses increased to $1.3 million amid higher consulting costs.
RenovoRx, Inc. (Nasdaq: RNXT) announced CEO Shaun Bagai will participate in a ROTH Capital webinar on October 27 at 1 p.m. ET. The discussion will focus on RenovoRx's mission to innovate oncology therapy through its RenovoTAMP treatment, which aims to improve quality of life and enhance survival for patients with difficult-to-treat cancers. Bagai will also review the ongoing Phase 3 TIGeR-PaC clinical trial, with its first results expected in Q4 2023. The public can register to attend and ask questions during the session.
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical firm specializing in localized treatment of solid tumors, is set to participate in two investor conferences in October 2022. CEO Shaun Bagai will present at the ROTH Inaugural Healthcare Opportunities Conference on October 6 and the LD Micro Main Event XV from October 25-27. He will discuss the company's therapy platform and address the challenges of treating pancreatic tumors. RenovoRx's lead product, RenovoGem, is in a Phase 3 trial targeting unresectable locally advanced pancreatic cancer.
RenovoRx, Inc. (NASDAQ: RNXT) recently announced Dr. Ripal Gandhi's presentation on Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer at the Symposium on Clinical Interventional Oncology held in Miami Beach, Florida, from September 23-25, 2022. The presentation discussed challenges with the standard chemotherapy for locally advanced pancreatic cancer and highlighted the potential of RenovoRx's RenovoTAMP therapy, which aims to enhance chemotherapy efficacy and reduce side effects. The ongoing TIGeR-PaC study is evaluating the company's product candidate, RenovoGem, for improved patient outcomes.
RenovoRx, a biopharmaceutical company specialized in treating challenging solid tumors, has appointed Angela Gill Nelms as Chief Operating Officer. Ms. Nelms brings extensive expertise in clinical trial management and innovation, previously serving as COO at Florence Healthcare. Under her leadership, RenovoRx aims to expedite its Phase 3 TIGeR-PaC clinical trial and launch a new trial for extrahepatic cholangiocarcinoma. This strategic move aims to enhance the company's operational capabilities and advance its mission to lead in oncology therapies.
RenovoRx, a biopharmaceutical company listed on Nasdaq under the symbol RNXT, will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. CEO Shaun Bagai is scheduled to present on September 12 at 7:00 a.m. ET, discussing the challenges in treating pancreatic tumors and the innovative RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy. One-on-one meetings will also be held with investors.
RenovoRx’s lead product, RenovoGem™, is under Phase 3 study for locally advanced pancreatic cancer.
RenovoRx, Inc. (Nasdaq: RNXT) reported its financial results for Q2 2022, revealing cash and cash equivalents of $10.8 million. R&D expenses rose to $1.4 million from $0.5 million year-over-year, while G&A expenses increased to $1.2 million from $0.3 million. The company reported a net loss of $2.6 million, up from $1.3 million in the previous year. Key developments include an upcoming interim analysis of the Phase 3 TIGeR-PaC clinical trial for pancreatic cancer and a new Phase 2/3 trial protocol submission. RenovoRx is advancing its proprietary RenovoTAMP therapy platform.